Olumiant (baricitinib and external corticosteroids in Phase 3 clinical trial scored the main endpoint)
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Asexual dermatitis is a serious chronic, recurrent skin diseaseThe main symptoms are itching, dry skin and inflammation, which can occur in any part of the bodyRecently, Lilly(http://and Incyte jointly announced that THE JAK inhibitor Olumiant (baricitinib) in combination with the external corticosteroids, in the treatment of patients with severe asexual dermatitis in the stage 3 clinicaltrial(http://the main endpointAbout Baricitinib
Baricitinib is a daily oral JAK inhibitor, and Baricitinib has been approved by the U.SFDA(http://to treat patients with moderate to severe active rheumatoid arthritis who are under-reacted to TNF inhibitor therapyIn the study
patients with moderate and severe atopic dermatitis received baricitinib in addition to standard epicortical steroid sparing steroids in a key Phase 3 clinical trial called BREEZE-AD7 The results showed that the combination of baricitinib with standard therapies significantly improved the severity of the disease Using a vIGA score of asexual dermatitis, the percentage of patients who reached the main end of the trial at the 16th week of treatment, with the proportion of patients who achieved skin symptom removal or almost elimination (vIGA-0,1) was significantly higher than in the placebo group
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
